Case Challenges with Antiplatelet Therapy

Dinner and Registration: 6:00PM - 6:30PM CT
Symposium: 6:30PM - 8:00PM CT

Venue: Marriot Marquis Chicago
Ballroom: Great Lakes FG
2121 South Prarie Avenue, Chicago, Illinois


Chair: Deepak Bhatt, MD, MPH

Faculty: Marc Bonaca, MD, MPH; Roxana Mehran, MD; PG Steg, MD

Registration for this program is now closed.

Finding the right balance between maintaining the efficacy of preventing ischemic events without incurring bleeding-related harm in patients with coronary artery disease (CAD) remains an issue in the "real-world " practice of cardiologists. An awareness of the multiple factors to consider when assessing ischemic risk and bleeding risk is required in order to tailor the intensity and duration of antiplatelet therapy after percutaneous coronary intervention (PCI) to the individual patient. Dual antiplatelet therapy (DAPT) remains the cornerstone of therapy for the prevention of ischemic complications after PCI. However, the reduction in risk of ischemic events with DAPT comes at a cost of increased bleeding; patients at high bleeding risk (HBR) may be effectively and safely managed with antiplatelet therapy bleeding risk-reduction strategies. Conversely, other patients at high ischemic risk after full-term DAPT may be candidates for either extended DAPT or dual pathway inhibition (DPI), consisting of aspirin (ASA) plus factor Xa inhibition. In this program, experts in the use of antiplatelet therapy (Program Chair Dr. Deepak Bhatt, with faculty members Dr. Marc Bonaca, Dr. Roxana Mehran, and Dr. Philippe Gabriel Steg) will describe best practices for assessing ischemic risk and bleeding risk after PCI, and in 3 challenging cases, supported by current clinical trial evidence, identify patients for bleeding risk-reduction strategies with antiplatelet therapy, and patients for consideration of prolonged dual therapy..

Educational Objectives: 

1. Discuss the multiple factors to be considered when assessing ischemic risk and bleeding risk after percutaneous coronary intervention (PCI).
2. Recognize diabetes mellitus as a criterion for increased ischemic risk.
3. Identify patients at high bleeding risk (HBR) and interpret clinical evidence using bleeding risk-reduction strategies with antiplatelet therapy.
4. Describe factors for consideration of extended dual antiplatelet therapy (DAPT) or dual pathway inhibition (DPI) and explain clinical trial results.

Accreditation & Credit Designation:
Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits^TM through its reciprocity agreements.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits ^TM from organizations accredited by the ACCME.

Educational Grant: This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Target Audience:  This educational activity is intended for clinicians who manage patients with cardiovascular disease.